Haemonetics outlines FY 2027 organic growth of 6%-9% with CSL Persona PLUS rollout through 2027
FROM THE WIRE · SEEKINGALPHA.COM
Haemonetics Q2 FY2027 earnings: raised revenue growth outlook, CSL rollout progress, and margin headwinds.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA raised revenue growth outlook for a mid-cap company can move its shares after results.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Haemonetics reported Q2 FY2027 earnings.
- 02The company raised its revenue growth outlook.
- 03The CSL Persona PLUS rollout continues through calendar 2027.
- 04Margin headwinds were also mentioned.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets